Heart failure in women – insights from the framingham heart study

Cardiovascular Drugs and Therapy

Volumn 29, Issue 4, 2015, Pages 377-390

  Kenchaiah, Satish ^a,b,c   Vasan, Ramachandran S ^b,d  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b FRAMINGHAM HEART STUDY   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarkers; Epidemiology; Framingham heart study; Gender; Heart failure; Incidence; Men; Mortality; Risk factors; Sex differences; Survival; Women

Indexed keywords

ADIPONECTIN; ALDOSTERONE; BIOLOGICAL MARKER; CYTOKINE; GALECTIN 3; GAMMA GLUTAMYLTRANSFERASE; GELATINASE B; HOMOCYSTEINE; LEPTIN; NATRIURETIC FACTOR; PHOSPHORUS; RESISTIN; SOMATOMEDIN C;

ALCOHOL CONSUMPTION; AORTA ROOT; ARTICLE; ATRIAL FIBRILLATION; CARDIAC PATIENT; CARDIOVASCULAR RISK; CAUSE OF DEATH; CLINICAL FEATURE; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSLIPIDEMIA; ELECTROCARDIOGRAPHY; FEMALE; HEALTH DISPARITY; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART RATE; HEMATOCRIT; HEREDITY; HUMAN; HYPERTENSION; INCIDENCE; LEUKOCYTE FUNCTION; OBESITY; PHYSICAL INACTIVITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QRS INTERVAL; SMOKING; SURVIVAL RATE; TELOMERE HOMEOSTASIS; VALVULAR HEART DISEASE; VASCULAR REMODELING; WOMEN'S HEALTH; ECHOCARDIOGRAPHY; PATHOPHYSIOLOGY; RISK; RISK FACTOR;

BIOMARKERS; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; HEART FAILURE; HUMANS; INCIDENCE; RISK; RISK FACTORS;

EID: 84943363249     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-015-6599-0     Document Type: Article

References (59)

1. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med. 1971; 285: 1441-6.
2. Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002; 347: 1397-402.
3. Velagaleti RS, Pencina MJ, Murabito JM, Wang TJ, Parikh NI, D'Agostino RB, et al. Long-term trends in the incidence of heart failure after myocardial infarction. Circulation. 2008; 118: 2057-62.
4. Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham heart study subjects. Circulation. 1993; 88: 107-15.
5. Kannel WB, D'Agostino RB, Silbershatz H, Belanger AJ, Wilson PW, Levy D. Profile for estimating risk of heart failure. Arch Intern Med. 1999; 159: 1197-204.
6. Ho JE, Lyass A, Lee DS, Vasan RS, Kannel WB, LarsonMG, et al. Predictors of new-onset heart failure: differences in preserved versus reduced ejection fraction. Circ Heart Fail. 2013; 6: 279-86.
7. Schnabel RB, Rienstra M, Sullivan LM, Sun JX, Moser CB, Levy D, et al. Risk assessment for incident heart failure in individuals with atrial fibrillation. Eur J Heart Fail. 2013; 15: 843-9.
8. Ho JE, Gona P, Pencina MJ, Tu JV, Austin PC, Vasan RS, et al. Discriminating clinical features of heart failure with preserved vs. Reduced ejection fraction in the community. Eur Heart J. 2012; 33: 1734-41.
9. Krumholz HM, Larson M, Levy D. Sex differences in cardiac adaptation to isolated systolic hypertension. Am J Cardiol. 1993; 72: 310-3.
10. Lam CS, Donal E, Kraigher-Krainer E, Vasan RS. Epidemiology and clinical course of heart failure with preserved ejection fraction. Eur J Heart Fail. 2011; 13: 18-28.
11. Andersson C, Vasan RS. Epidemiology of heart failure with preserved ejection fraction. Heart Fail Clin. 2014; 10: 377-88.
12. Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D'Agostino RB, Kannel WB, et al. Lifetime risk for developing congestive heart failure: the Framingham heart study. Circulation. 2002; 106: 3068-72.
13. Levy D, LarsonMG, Vasan RS, KannelWB, Ho KK. The progression from hypertension to congestive heart failure. JAMA. 1996; 275: 1557-62.
14. Vasan RS, Levy D. The role of hypertension in the pathogenesis of heart failure. A clinical mechanistic overview. Arch Intern Med. 1996; 156: 1789-96.
15. Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG, et al. Obesity and the risk of heart failure. N Engl J Med. 2002; 347: 305-13.
16. Walsh CR, Larson MG, Evans JC, Djousse L, Ellison RC, Vasan RS, et al. Alcohol consumption and risk for congestive heart failure in the Framingham heart study. Ann Intern Med. 2002; 136: 181-91.
17. Lee DS, Pencina MJ, Benjamin EJ, Wang TJ, Levy D, O'Donnell CJ, et al. Association of parental heart failure with risk of heart failure in offspring. N Engl J Med. 2006; 355: 138-47.
18. Dhingra R, PencinaMJ, Wang TJ, Nam BH, Benjamin EJ, Levy D, et al. Electrocardiographic qrs duration and the risk of congestive heart failure: the Framingham heart study. Hypertension. 2006; 47: 861-7.
19. Velagaleti RS, Massaro J, Vasan RS, Robins SJ, KannelWB, Levy D. Relations of lipid concentrations to heart failure incidence: the Framingham heart study. Circulation. 2009; 120: 2345-51.
20. Kraigher-Krainer E, Lyass A, Massaro JM, Lee DS, Ho JE, Levy D, et al. Association of physical activity and heart failure with preserved vs. reduced ejection fraction in the elderly: the Framingham heart study. Eur J Heart Fail. 2013; 15: 742-6.
21. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974; 34: 29-34.
22. Dhingra R, Vasan RS. Diabetes and the risk of heart failure. Heart Fail Clin. 2012; 8: 125-33.
23. Galderisi M, Anderson KM, Wilson PW, Levy D. Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the framingham heart study). Am J Cardiol. 1991; 68: 85-9.
24. RutterMK, Parise H, Benjamin EJ, Levy D, LarsonMG, Meigs JB, et al. Impact of glucose intolerance and insulin resistance on cardiac structure and function: sex-related differences in the Framingham heart study. Circulation. 2003; 107: 448-54.
25. Lee DS, Massaro JM, Wang TJ, Kannel WB, Benjamin EJ, Kenchaiah S, et al. Antecedent blood pressure, body mass index, and the risk of incident heart failure in later life. Hypertension. 2007; 50: 869-76.
26. Kenchaiah S, Gaziano JM, Vasan RS. Impact of obesity on the risk of heart failure and survival after the onset of heart failure. Med Clin N Am. 2004; 88: 1273-94.
27. Cheng S, McCabe EL, LarsonMG, ChenMH, Osypiuk E, Lehman BT, et al. Left ventricular mechanical function: clinical correlates, heritability, and association with parental heart failure. Eur J Heart Fail. 2015; 17: 44-50.
28. Lam CS, Liu X, Yang Q, Larson MG, Pencina MJ, Aragam J, et al. Familial aggregation of left ventricular geometry and association with parental heart failure: the Framingham heart study. Circ Cardiovasc Genet. 2010; 3: 492-8.
29. Lam CS, Lyass A, Kraigher-Krainer E, Massaro JM, Lee DS, Ho JE, et al. Cardiac dysfunction and noncardiac dysfunction as precursors of heart failure with reduced and preserved ejection fraction in the community. Circulation. 2011; 124: 24-30.
30. Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham heart study. Circulation. 2003; 107: 2920-5.
31. Vasan RS, Larson MG, Benjamin EJ, Evans JC, Levy D. Left ventricular dilatation and the risk of congestive heart failure in people without myocardial infarction. N Engl J Med. 1997; 336: 1350-5.
32. Wang TJ, Evans JC, Benjamin EJ, Levy D, LeRoy EC, Vasan RS. Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation. 2003; 108: 977-82.
33. Lam CS, Gona P, Larson MG, Aragam J, Lee DS, Mitchell GF, et al. Aortic root remodeling and risk of heart failure in the framingham heart study. JACC Heart Fail. 2013; 1: 79-83.
34. Velagaleti RS, Gona P, Pencina MJ, Aragam J, Wang TJ, Levy D, et al. Left ventricular hypertrophy patterns and incidence of heart failure with preserved versus reduced ejection fraction. Am J Cardiol. 2014; 113: 117-22.
35. Vasan RS, LarsonMG, Levy D. Determinants of echocardiographic aortic root size. The Framingham heart study. Circulation. 1995; 91: 734-40.
36. Cheng S, Xanthakis V, Sullivan LM, LiebW, Massaro J, Aragam J, et al. Correlates of echocardiographic indices of cardiac remodeling over the adult life course: longitudinal observations from the Framingham heart study. Circulation. 2010; 122: 570-8.
37. Sundstrom J, Sullivan L, Selhub J, Benjamin EJ, D'Agostino RB, Jacques PF, et al. Relations of plasma homocysteine to left ventricular structure and function: the Framingham heart study. Eur Heart J. 2004; 25: 523-30.
38. Vasan RS, Beiser A, D'Agostino RB, Levy D, Selhub J, Jacques PF, et al. Plasma homocysteine and risk for congestive heart failure in adults without priormyocardial infarction. JAMA. 2003; 289: 1251-7.
39. Vasan RS, Sullivan LM, Roubenoff R, Dinarello CA, Harris T, Benjamin EJ, et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham heart study. Circulation. 2003; 107: 1486-91.
40. Vasan RS, Sullivan LM, D'Agostino RB, Roubenoff R, Harris T, Sawyer DB, et al. Serum insulin-like growth factor i and risk for heart failure in elderly individuals without a previous myocardial infarction: the Framingham heart study. Ann InternMed. 2003; 139: 642-8.
41. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med. 2004; 350: 655-63.
42. Frankel DS, Vasan RS, D'Agostino Sr RB, Benjamin EJ, Levy D, Wang TJ, et al. Resistin, adiponectin, and risk of heart failure the framingham offspring study. J Am Coll Cardiol. 2009; 53: 754-62.
43. LiebW, Sullivan LM, Harris TB, Roubenoff R, Benjamin EJ, Levy D, et al. Plasma leptin levels and incidence of heart failure, cardiovascular disease, and total mortality in elderly individuals. Diabetes Care. 2009; 32: 612-6.
44. Velagaleti RS, Gona P, Larson MG, Wang TJ, Levy D, Benjamin EJ, et al. Multimarker approach for the prediction of heart failure incidence in the community. Circulation. 2010; 122: 1700-6.
45. Dhingra R, Gona P, Benjamin EJ, Wang TJ, Aragam J, D'Agostino Sr RB, et al. Relations of serum phosphorus levels to echocardiographic left ventricular mass and incidence of heart failure in the community. Eur J Heart Fail. 2010; 12: 812-8.
46. Dhingra R, Gona P, Wang TJ, Fox CS, D'Agostino Sr RB, Vasan RS. Serum gamma-glutamyl transferase and risk of heart failure in the community. Arterioscler Thromb Vasc Biol. 2010; 30: 1855-60.
47. Ho JE, Liu C, Lyass A, Courchesne P, Pencina MJ, Vasan RS, et al. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol. 2012; 60: 1249-56.
48. Coglianese EE, Qureshi MM, Vasan RS, Wang TJ, Moore LL. Usefulness of the blood hematocrit level to predict development of heart failure in a community. Am J Cardiol. 2012; 109: 241-5.
49. Sundstrom J, Vasan RS. Homocysteine and heart failure: a review of investigations from the framingham heart study. Clin Chem Lab Med. 2005; 43: 987-92.
50. Wang TJ, Larson MG, Levy D, Leip EP, Benjamin EJ, Wilson PW, et al. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am J Cardiol. 2002; 90: 254-8.
51. Lam CS, Cheng S, Choong K, Larson MG, Murabito JM, Newton-Cheh C, et al. Influence of sex and hormone status on circulating natriuretic peptides. J Am Coll Cardiol. 2011; 58: 618-26.
52. Vasan RS, Benjamin EJ, Larson MG, Leip EP, Wang TJ, Wilson PW, et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. JAMA. 2002; 288: 1252-9.
53. Lieb W, Sullivan LM, Aragam J, Harris TB, Roubenoff R, Benjamin EJ, et al. Relation of serum leptin with cardiac mass and left atrial dimension in individuals >70 years of age. Am J Cardiol. 2009; 104: 602-5.
54. Velagaleti RS, Gona P, Levy D, Aragam J, Larson MG, Tofler GH, et al. Relations of biomarkers representing distinct biological pathways to left ventricular geometry. Circulation. 2008; 118: 2252-8.
55. Vasan RS, Evans JC, Benjamin EJ, Levy D, Larson MG, Sundstrom J, et al. Relations of serum aldosterone to cardiac structure: gender-related differences in the framingham heart study. Hypertension. 2004; 43: 957-62.
56. Vasan RS, Evans JC, Larson MG, Wilson PW, Meigs JB, Rifai N, et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med. 2004; 351: 33-41.
57. Sundstrom J, Evans JC, Benjamin EJ, Levy D, LarsonMG, Sawyer DB, et al. Relations of plasmamatrixmetalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: the Framingham heart study. Circulation. 2004; 109: 2850-6.
58. Vasan RS, Demissie S, Kimura M, Cupples LA, White C, Gardner JP, et al. Association of leukocyte telomere length with echocardiographic left ventricular mass: the Framingham heart study. Circulation. 2009; 120: 1195-202.
59. Lee DS, Gona P, Albano I, LarsonMG, Benjamin EJ, Levy D, et al. A systematic assessment of causes of death after heart failure onset in the community: impact of age at death, time period, and left ventricular systolic dysfunction. Circ Heart Fail. 2011; 4: 36-43.